Differential processing of osteopontin characterizes the proliferative vascular smooth muscle cell phenotype induced by allylamine

Journal of Cellular Biochemistry

Volumn 65, Issue 2, 1997, Pages 267-275

  Parrish, Alan R ^a   Ramos, Kenneth S ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

Author keywords

allylamine; atherosclerosis; osteopontin; vascular injury; vascular smooth muscle cells

Indexed keywords

ALLYLAMINE; MESSENGER RNA; METHIONINE; OSTEOPONTIN; THROMBIN; THYMIDINE;

ANIMAL CELL; ARTICLE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; MALE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; RAT; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

ANIMALIA;

EID: 0030901970     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4644(199705)65:2<267::AID-JCB12>3.0.CO;2-F     Document Type: Article

References (37)

1. Behrend EI, Craig AM, Wilson SM, Denhardt DT, Chambers AF (1994): Reduced malignancy of ras-transformed NIH3T3 cells expressing antisense osteopontin mRNA. Cancer Res 54:832-837.
2. Boor PJ, Nelson TJ, Chieco P (1980): Allylamine cardiotoxicity. II. Histopathology and histochemistry. Am J Pathol 100:739-751.
3. Bowes III RC, Ramos KS (1993): Allylamine enhances c-Ha-ras protooncogene expression in rat aortic smooth muscle cells. Toxicol Lett 66:263-272.
4. Bradford MM (1976): A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
5. Chen J, Singh K, Mukherjee BB, Sodek J (1993): Developmental expression of osteopontin (OPN) mRNA in rat tissues: Evidence for a role of OPN in bone formation and resorption. Matrix 13:113-123.
6. Choi ET, Engel L, Callow AD, Sun S, Trachtenberg J, Santoro S, Ryan US (1994): Inhibition of neointimal hyperplasia by blocking alpha v beta 3 integrin with a small peptide antagonist gpenGRGDSPCA. J Vasc Surg 19:125-134.
7. Chomczynski P, Sacchi N (1987): Single step method RNA isolation by acid guanidium thiocyanate phenol-chloroform extraction. Anal Biochem 162:156-159.
8. Cox LR, Ramos K (1990): Allylamine-induced phenotypic modulation of aortic smooth muscle cells. J Exp Pathol 71:11-18.
9. Denhardt DT, Guo X (1993): Osteopontin: A protein with diverse functions. FASEB J 7:1475-1482.
10. Fager G (1995): Thrombin and proliferation of vascular smooth muscle cells. Circ Res 77:645-650.
11. Gadeau AP, Campan M, Millet D, Candresse T, Desgranges C (1993): Osteopontin overexpression is associated with arterial smooth muscle cell proliferation in vitro. Arter Thromb 13:120-125.
12. Gardner HA, Berse B, Senger DR (1994): Specific reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat1 fibroblasts. Oncogene 9:2321-2326.
13. Giachelli C, Bae N, Lombardi D, Majesky M, Schwartz S (1991): Molecular cloning and characterization of 2B7, a rat mRNA which distinguishes smooth muscle cell phenotypes in vitro and is identical to osteopontin (secreted phosphoprotein 1, 2aR). Biochem Biophys Res Commun 177:867-873.
14. Giachelli CM, Bae N, Almeida M, Denhardt DT, Alpers CE, Schwartz SM (1993): Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest 92:1686-1696.
15. Hwang S-M, Lopez CA, Heck DE, Gardner CR, Laskin DL, Laskin JD, Denhardt DT (1994): Osteopontin inhibits induction of nitric oxide synthase activity by inflammatory mediators in mouse kidney epithelial cells. J Biol Chem 269:711-715.
16. Laemmli UK (1970): Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
17. Lalich JJ, Allen JR, Paik WCW (1972): Myocardial fibrosis and smooth muscle cell hyperplasia in coronary arteries of allylamine-fed rats. Am J Pathol 66:225-233.
18. Liaw L, Almeida M, Hart CE, Schwartz SM, Giachelli CM (1994): Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro. Circ Res 74:214-224.
19. Liaw L, Skinner MP, Raines EW, Ross R, Cheresh DA, Schwartz SM, Giachelli CM (1995): The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. J Clin Invest 95:713-724.
20. Matsuno H, Stassen JM, Vermylen J, Deckmyn H (1994): Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation. Circulation 90:2203-2206.
21. McNamara CA, Sarembock IJ, Gimple LW, Fenton JW, Coughlin SR, Owens GK (1993): Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by proteolytically activated receptor. J Clin Invest 91:94-98.
22. Olberg A, Franzen A, Heinegard D (1986): Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an arg-gly-asp cell-binding sequence. Proc Natl Acad Sci USA 83:8819-8823.
23. Ramos K (1990): Comparative angiotoxic responses of avian and rodent species: Implications in atherogenesis. J Toxicol Environ Health 29:357-376.
24. Ramos K, Cox LR (1987): Primary cultures of aortic smooth muscle cells: I. An in vitro model to study xenobiotic-induced vascular cytotoxicity. In Vitro Cell Dev Biol 23: 288-296.
25. Ramos KS, Parrish AR (1995): Growth-related signaling as a target of toxic insult in vascular smooth muscle cells: Implications in atherogenesis. Life Sci 57:627-635.
26. Ramos K, Grossman SL, Cox LR (1988): Allylamine-induced vascular toxicity in vitro: Prevention by semicarbazide-sensitive amine oxidase inhibitors. Toxicol Appl Pharmacol 96:61-71.
27. Ramos KS, Weber TJ, Liau G (1993): Altered protein secretion and extracellular matrix deposition is associated with the proliferative phenotype induced by allylamine in aortic smooth muscle cells. Biochem J 289:57-63.
28. Ross R (1993): The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 362:801-809.
29. Sauk JJ, Van Kampen CL, Norris K, Foster R, Somerman MJ (1990): Expression of constitutive and inducible HAS70 and HSP47 is enhanced in cells persistently spread on OPN or collagen. Biochem Biophys Res Commun 172:135-142.
30. Schwartz SM, deBlois D, O'Brien ERM (1995): The intima: Soil for atherosclerosis and restenosis. Circ Res 77:445-465.
31. Senger DR, Perruzzi CA, Papadopoulos A (1989): Elevated expression of secreted phosphoprotein 1 (osteopontin, 2ar) as a consequence of neoplastic transformation. Anticancer Res 9:1291-1300.
32. Senger DR, Perruzzi CA, Papdopoulos-Sergiou A, Van de Water L (1994): Adhesive properties of osteopontin: Regulation by a naturally occurring thrombin-cleavage in close proximity to the GRGDS cell-binding domain. Mol Biol Cell 5:565-574.
33. 3 integrin, osteopontin and thrombin. Am J Pathol 149:293-305.
34. Su ZZ, Austin VN, Zimmer SG, Fischer PB (1993): Defining the critical gene expression changes associated with expression and suppression of the tumorigenic and metastatic phenotype in Ha-ras-transformed cloned rat embryo fibroblast cells. Oncogene 8:1211-1219.
35. Xuan J-W, Hota C, Chambers AF (1994): Recombinant GST-human osteopontin fusion protein is functional in RGD-dependent cell adhesion. J Cell Biochem 54:247-255.
36. Young MF, Kerr JM, Termine JD, Wewer UM, Wang MG, McBride OW, Fisher LW (1990): cDNA cloning, mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin (OPN). Genomics 7:491-502.
37. Yue T-L, McKenna PJ, Ohlstein EH, Farach-Carson MC, Butler WT, Johanson K, McDevitt P, Feuerstein GZ, Stadel JM (1994): Osteopontin-stimulated vascular smooth muscle cell migration is mediated by β3 integrin. Exp Cell Res 214:459-464.